中国神经再生研究(英文版) ›› 2017, Vol. 12 ›› Issue (9): 1418-1421.doi: 10.4103/1673-5374.215244

• 综述:退行性病与再生 • 上一篇    下一篇

α7烟碱受体激动剂治疗神经变性疾病神经炎症的治疗潜力

  

  • 收稿日期:2017-08-03 出版日期:2017-09-15 发布日期:2017-09-15

Therapeutic potential of α7 nicotinic receptor agonists to regulate neuroinflammation in neurodegenerative diseases

Laura Foucault-Fruchard1, 2, Daniel Antier1, 2   

  1. 1 UMR INSERM U930, Université François Rabelais, Tours, France
    2 CHRU de Tours, Hôpital Bretonneau, Tours, France
  • Received:2017-08-03 Online:2017-09-15 Published:2017-09-15
  • Contact: Laura Foucault-Fruchard,laura.foucault@univ-tours.fr.

摘要:

 

 

orcid:0000-0002-8037-9457(Laura Foucault-Fruchard)

Abstract:

Neurodegenerative diseases, such as Alzheimer’s, Parkinson’s and Huntington’s diseases, are all character­ized by a component of innate immunity called neuroinflammation. Neuronal loss and neuroinflammation are two phenomena closely linked. Hence, the neuroinflammation is a relevant target for the management of the neurodegenerative diseases given that, to date, there is no treatment to stop neuronal loss. Several studies have investigated the potential effects of activators of alpha 7 nicotinic acetylcholine receptors in animal models of neurodegenerative diseases. These receptors are widely distributed in the central nervous system. After activation, they seem to mediate the cholinergic anti-inflammatory pathway in the brain. This anti-inflammatory pathway, first described in periphery, regulates activation of microglial cells considered as the resident macrophage population of the central nervous system. In this article, we shortly review the agonists of the alpha 7 nicotinic acetylcholine receptors that have been evaluated in vivo and we focused on the selective positive allosteric modulators of these receptors. These compounds represent a key element to enhance receptor activity only in the presence of the endogenous agonist.

Key words: α7 nicotinic receptors, cholinergic anti-inflammatory pathway, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, neuroinflammation, neurodegeneration, positive allosteric modulators